Last reviewed · How we verify
NCT05243524: AVALON
Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Phase 2 trial testing Maveropepimut-S in Platinum-resistant Epithelial Ovarian Cancer in 16 participants. Terminated before completion.
24 July 2023
Quick facts
| Lead sponsor | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 5 August 2022 |
| Primary completion | 24 July 2023 |
| Estimated completion | 31 August 2023 |
| Sites | 6 locations across Canada, United States, Puerto Rico |
Drugs / interventions tested
- Maveropepimut-S — full drug profile →
- Cyclophosphamide 50mg — full drug profile →
Conditions studied
- Platinum-resistant Epithelial Ovarian Cancer — all drugs for Platinum-resistant Epithelial Ovarian Cancer →
Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.) — full company profile →
Who can join
18 and older, female only, with Platinum-resistant Epithelial Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.
Yu M, Yang W, Yue W, Chen Y. · · 2022 · cited 35× · PMID 36257824 · DOI 10.1002/advs.202204335 -
Bioresponsive engineered nanoparticles for immunomodulation.
Hegde M, Mishra A, Banerjee R, Bintee B, et al · · 2025 · cited 4× · PMID 41162977 · DOI 10.1186/s12916-025-04305-6 -
Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation.
Deb VK, Mukherjee A, Pathak S, Paul S, et al · · 2026 · PMID 42040777 · DOI 10.3389/fbioe.2026.1775442 -
Targeting Survivin: Now I Become Death, the Destroyer of Cells.
Fanuzzi M, Zheng S, Horbinski CM, Shaaban MA, et al · · 2025 · PMID 41373575 · DOI 10.3390/ijms262311417
Verify or expand the search:
- PubMed search for NCT05243524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other ImmunoVaccine Technologies, Inc. (IMV Inc.) trials
Trials by the same sponsor.
- NCT03836352 — Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects · Phase 2 · active not recruiting
- NCT03332576 — Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05243524 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05243524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing